metacrine.com
Open in
urlscan Pro
35.225.31.70
Public Scan
Submitted URL: http://metacrine.com/
Effective URL: https://metacrine.com/
Submission: On October 05 via api from US — Scanned from DE
Effective URL: https://metacrine.com/
Submission: On October 05 via api from US — Scanned from DE
Form analysis 1 forms found in the DOM
GET https://metacrine.com/
<form role="search" method="get" class="search-form" action="https://metacrine.com/">
<label>
<span class="screen-reader-text">Search for:</span>
<input type="search" class="search-field" placeholder="Search …" value="" name="s">
</label>
<input type="submit" class="search-submit" value="Search">
</form>Text Content
Search
* Our Company
* Overview
* Leadership
* Board of Directors
* Programs
* Pipeline
* IBD
* NASH
* Publications
* Investors
* Overview
* News Releases
* Events & Presentations
* Stock Information
* Corporate Governance
* Governance Documents
* Committee Composition
* Financials & Filings
* Sec Filings
* Investor Resources
* Email Alerts
* IR Contact
* FAQs
* News
* Careers
* Contact
Search for:
THERE ARE MORE THAN 3 MILLION PEOPLE IN THE UNITED STATES WITH IBD.
THERE ARE MORE THAN 3 MILLION PEOPLE IN THE UNITED STATES WITH IBD.
OUR COMPANY
We are a clinical-stage biopharmaceutical company pioneering differentiated
therapies for patients with GI and liver diseases.
LATEST NEWS
September 06, 2022
EQUILLIUM TO ACQUIRE METACRINE IN ALL-STOCK TRANSACTION
--------------------------------------------------------------------------------
August 09, 2022
METACRINE REPORTS SECOND-QUARTER 2022 RESULTS
PROGRAMS
Our most advanced program targets the farnesoid X receptor (FXR) which is
central to modulating GI and liver diseases.
© 2022 Metacrine | 4225 Executive Square, Suite 600, San Diego, CA 92037
* Our Company
▼
* Overview
* Leadership
* Board of Directors
* Programs
▼
* Pipeline
* IBD
* NASH
* Publications
* Investors
▼
* Overview
* News Releases
* Events & Presentations
* Stock Information
* Corporate Governance
▼
* Governance Documents
* Committee Composition
* Financials & Filings
▼
* Sec Filings
* Investor Resources
▼
* Email Alerts
* IR Contact
* FAQs
* News
* Careers
* Contact